- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02154919
Non-culprit Vessels for ST-Segment Elevation Myocardial Infarction (CPVsSPCI)
May 31, 2014 updated by: Peng Jian Jun, Beijing Shijitan Hospital, Capital Medical University
Conservative Pharmacotherapy Versus Staged Percutaneous Coronary Intervention on Non-culprit Vessels for ST-Segment Elevation Myocardial Infarction Patients With Multivessel Disease
To compare the different effect of conservative pharmacotherapy and Staged Percutaneous Coronary Intervention (SPCI) on significant non-culprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) at presentation remains controversial
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
306
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100038
- Beijing Shijitan Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
STEMI patients after culprit vessels treated by PPCI
Description
Inclusion Criteria:
- age 18 to 75 with continuous ischemic chest pain for ≥ 30 minutes and ST-segment of electrocardiographic leads between V2 and V3 elevated ≥ 0.2 mV (or ≥ 0.1 mV in ≥ 2 other continuous electrocardiographic leads), cardiac troponin I (cTn I) elevation of > 0.05 ng/ml, coronary arteriography within 12 hours after the onset of symptoms indicating lesion in culprit vessel with thrombolysis in myocardial infarction (TIMI) flow grade 0 to 1, merely underwent PPCI. Additionally, coronary arteriography corroborates lesions in non-culprit vessel (Besides the culprit vessel, there are ≥ 70% stenoses in one or more coronary vessels in which diameters were ≥ 2 mm).
Exclusion Criteria:
- left main coronary artery disease, cardiogenic shock, complete left bundle branch block (CLBBB) PPCI treated culprit and non-culprit vessels, PPCI failure patients with postsurgical haemodynamic instability or spontaneous ischemia, ≥ 70% stenoses of vessels remained during the hospitalization after staged PCI, history of PCI or Coronary Artery Bypass Grafting (CABG), history of chronic cardiac failure, bleeding diathesis, prior administration of thrombolytic therapy, known thrombopenia or leucopenia, sever liver and kidney dysfunction, active infection, immune system and connective tissue diseases, known contraindications to aspirin or heparin, life expectancy < 1 year, had major procedure within 3 months, uncontrolled hypertension, ischemic stroke within 30 days, hemorrhagic stroke, intracranial diseases including and arteriovenous malformation, extensive traumatic cerebral infarction within 6 weeks, oral anticoagulant therapy, severe myocardial infarction related complications and perioperative death
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
complete revascularization group
this group underwent second PCI procedure on the non-culprit vessels and reveived 100-120 IU/kg unfractionated heparin during PPCI, followed by 3 days administration of low molecular weight heparin or Fondaparinux sodium after procedure.
Patients in the CP group and CR group after second PCI procedure were given conservative medicine such as Statins which were not contraindicated to the patients.
|
|
conservative pharmacotherapy group
patients in conservative group undergoing pharmacotherapy after PPCI.
The drugs were the same between two groups.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Major Adverse Cardiovascular Events
Time Frame: 360days
|
360days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2011
Primary Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
May 31, 2014
First Submitted That Met QC Criteria
May 31, 2014
First Posted (Estimate)
June 3, 2014
Study Record Updates
Last Update Posted (Estimate)
June 3, 2014
Last Update Submitted That Met QC Criteria
May 31, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CPVsSPCI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ST-Segment Elevation Myocardial Infarction
-
Inha University HospitalCompletedST Segment Elevation Myocardial Infarction | Non-ST Segment Elevation Myocardial InfarctionKorea, Republic of
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
RenJi HospitalCompletedST Segment Elevation Myocardial Infarction
-
Dong-A UniversityTerminatedST-Segment Elevation Myocardial InfarctionKorea, Republic of
-
Azienda Ospedaliera San Camillo ForlaniniUnknownST Segment Elevation Myocardial InfarctionItaly
-
Jinan Central HospitalUnknownST-Segment Elevation Myocardial InfarctionChina
-
Rigshospitalet, DenmarkRecruitingST Segment Elevation Myocardial InfarctionDenmark
-
RenJi HospitalUnknownST Segment Elevation Myocardial InfarctionChina
-
RenJi HospitalUnknownST Segment Elevation Myocardial InfarctionChina
-
UOSD Emodinamica Diagnostica e InterventisticaUnknownST Segment Elevation Myocardial InfarctionItaly
Clinical Trials on Percutaneous coronary intervention
-
Mid and South Essex NHS Foundation TrustImperial College LondonRecruitingStable Angina | Chronic Total Occlusion of Coronary ArteryUnited Kingdom
-
University Hospital, SaarlandCompletedAcute Myocardial InfarctionGermany
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedCoronary Artery DiseaseChina
-
University Hospital of PatrasCompletedCoronary Artery Bypass SurgeryGreece
-
Yonsei UniversityUnknownCoronary Artery Disease | Stable Angina | Unstable AnginaKorea, Republic of
-
ECRI bvBoston Scientific Corporation; Philips HealthcareActive, not recruitingLeft Main Coronary Artery StenosisSpain, United Kingdom, Italy
-
Herlev and Gentofte HospitalUnknownCoronary Heart Disease | Ischemic Heart Disease | Stable AnginaDenmark
-
RobocathCompletedCoronary Artery Disease | Percutaneous Coronary InterventionFrance, Belgium, Luxembourg, Netherlands
-
University College, LondonNational Institute for Cardiovascular Outcomes Research; British Cardiovascular... and other collaboratorsCompletedPercutaneous Coronary InterventionUnited Kingdom
-
Niels Ramsing HolmJohnson & JohnsonUnknown